Ann: IMU Meets Endpoints in Phase 1b Gastric Cancer Trial, page-115

I quit my job in banking and put all my money on this stock. If HerVax does well in phase 2 then our company should have an acquisition value of about $500-$700m. This is looking promising given that our latest announcement was so positive. For all we know >30% reduction in tumor isn’t specific.. nor is the stable disease found in the other patients. Remember, these are patients who are almost 6 feet under - a remarkable achievement and god knows what else our antibodies can prevent in earlier stages and with a bigger sample size.

What amazes me, is that not only will HerVax value us enormously, but the vast list of other patented technologies in our pipeline have the potential too as well. Our future value is hard to put a figure on. 

I’ve spoken with the number one brain surgeon in the country and a doctor who is one of the industry heads in Australia, regularly on television. This is the hottest sector in biotech and if the best scientists and oncologist professors are with us... think iPhone to the Nokia. 

Enjoy the festivities